Novellus

Novellus is a biotechnology company dedicated to developing engineered cell therapies. The company uses its non-immunogenic mRNA molecules to safely and efficiently reprogram and genetically edit cells. They design precision medicines for patient subgroups and select from their technology toolbox for in vivo, ex vivo, allogeneic, and autologous delivery. The Novellus platform enables high-level expression of gene-editing and cell-reprogramming proteins to achieve highly specific gene repair as well as autologous and allogeneic cell therapies. The company is advancing its lead program through preclinical studies, a breakthrough therapy targeting a rare skin disease.